Table 2

Angiographic characteristics

SVD (n=1411; 70%)MVD—CTO (n=447; 22%)MVD +1 CTO (n=145; 7.2%)MVD >1 CTO (n=17; 0.8%)p Value
Radial access, n (%)1365 (97)414 (93)120 (83)10 (59)<0.0001
IABP, n (%)40 (3)41 (9)31 (21)4 (29)<0.0001
Tracheal intubation, n (%)27 (2)20 (4)12 (8)7 (41)<0.0001
Single vessel disease, n (%)1411 (100)000<0.0001
2-vessel disease, n (%)0341 (76)91 (63)0
3-vessel disease, n (%)0106 (24)54 (37)17 (100)
IRA LM, n (%)1 (0.1)8 (2)3 (2)0<0.0001
IRA LAD, n (%)593 (42)138 (31)67 (46)10 (59)<0.0001
IRA RCA, n (%)641 (45)229 (51)51 (35)2 (12)0.0002
IRA CX, n (%)176 (12)72 (16)24 (17)5 (29)0.036
TIMI flow 0 pre-PCI, n (%)802 (57)273 (61)86 (59)7 (41)0.23
Symptom onset to hospital time (h, median, IQR)3.2 (1.7, 6.1)3.4 (1.9, 5.9)3.8 (2.0, 7.4)4.1 (2.1, 9.2)0.27
Ischaemic time (h, median, IQR)4.0 (2.4, 7.1)4.3 (2.6, 7.2)4.8 (2.7, 9.4)5.7 (3.2, 10.7)0.05
Door to balloon time (min, median, IQR)36 (27, 62)39 (27, 70)40 (29, 65)96 (43, 146)0.0005
Use of GPI, n (%)1035 (73)296 (66)87 (60)4 (24)<0.0001
TIMI flow 0/1 post-PCI, n (%)24 (2)15 (3)9 (6)3 (17)<0.0001
Angiographic success, n (%)1136 (81)307 (69)105 (72)11 (64)<0.0001
MBG 0/1, n (%)100 (8)48 (11)20 (15)5 (29)<0.0001
Stenting, n (%)1384 (98)430 (96)132 (91)14 (82)<0.0001
CABG ≤30 days3 (0.2)24 (5)9 (6)1 (6)<0.0001
LVEF (%)53±1350±1443±1525±13<0.0001
LVEF <40%, n (%)241 (19)89 (23)57 (46)14 (87)<0.0001
Peak CK-MB (μg/l, median, IQR)140 (62, 270)142 (57, 264)142 (70, 333)337 (205, 460)0.0059
  • Angiographic success: <20% residual stenosis+IMI 3 flow post-PCI.

  • Other abbreviations as in table 1.

  • IRA, infarct-related artery; LM, left main; LAD, left anterior descending artery; RCA, right coronary artery; CX, left circumflex artery; GPI, Glycoproteins platelet inhibitors; TIMI, thrombolysis In myocardial infarction; MBG, myocardial blush grade; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; CK-MB, Serum myocardial band of creatine kinase; F-U, follow-up.